Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2023-05 Issue:10388 Volume:401 Page:1571-1583
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Erba Harry P,Montesinos Pau,Kim Hee-Je,Patkowska Elżbieta,Vrhovac Radovan,Žák Pavel,Wang Po-Nan,Mitov Tsvetomir,Hanyok James,Kamel Yasser Mostafa,Rohrbach Jaime E Connolly,Liu Li,Benzohra Aziz,Lesegretain Arnaud,Cortes Jorge,Perl Alexander E,Sekeres Mikkael A,Dombret Hervé,Amadori Sergio,Wang Jianxiang,Levis Mark J,Schlenk Richard F

Publisher

Elsevier BV

Subject

General Medicine

Reference39 articles.

1. Targeting FLT3 mutations in AML: review of current knowledge and evidence;Daver;Leukemia,2019

2. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status;Cortes;J Clin Oncol,2013

3. Acute myeloid leukemia;Döhner;N Engl J Med,2015

4. Acute myeloid leukemia: a comprehensive review and 2016 update;De Kouchkovsky;Blood Cancer J,2016

5. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies;Kennedy;Front Oncol,2020

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity;European Journal of Medicinal Chemistry;2024-12

2. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects;European Journal of Medicinal Chemistry;2024-10

3. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML;Blood Advances;2024-09-24

4. Maintenance Therapy in Acute Myeloid Leukemia;American Journal of Clinical Oncology;2024-09-06

5. Distinct FLT3 Pathways Gene Expression Profiles in Pediatric De Novo Acute Lymphoblastic and Myeloid Leukemia with FLT3 Mutations: Implications for Targeted Therapy;International Journal of Molecular Sciences;2024-09-04